PMID- 34461791
OWN - NLM
STAT- MEDLINE
DCOM- 20211102
LR  - 20220531
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 22
IP  - 16
DP  - 2021 Nov
TI  - Novel approaches to pharmacological management of type 2 diabetes in Japan.
PG  - 2235-2249
LID - 10.1080/14656566.2021.1974401 [doi]
AB  - INTRODUCTION: Newly developed anti-diabetic medications have had multiple 
      activities, beyond a blood glucose-lowering effect. Current drugs for treating 
      type 2 diabetes mellitus (T2DM) are based on the use of gastrointestinal 
      hormones. Representative incretin preparations, such as those with glucagon-like 
      peptide (GLP)-1 or gastric inhibitory polypeptide (GIP) activity, aim to provide 
      new means of controlling blood glucose levels, body weight, and lipid metabolism. 
      In this manuscript, the pathophysiology of T2DM and the activities and 
      characteristics of novel diabetic drugs are reviewed in the context of the 
      Japanese population. This review also highlights the need for novel medicines to 
      overcome the accompanying challenges. Finally, the author provides the reader 
      with their expert perspectives. The incidence of T2DM has been increasing in the 
      aging of Japanese society. In older people, medical development should focus on 
      safety, easier self-administration, and the relief of caregiver burden in terms 
      of continuous administration. In the young, the focus should be on effectiveness, 
      with a particular emphasis on the protection of organs, increasing the ease of 
      adherence, and safety. Novel medicines will need to push the envelope in these 
      areas.
FAU - Kaneko, Shizuka
AU  - Kaneko S
AD  - Department of Diabetes/Endocrinology/Metabolism, Takatsuki Red Cross Hospital, 
      Takatsuki, Osaka, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20211014
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Blood Glucose)
RN  - 0 (Incretins)
RN  - 0 (Insulin)
RN  - 59392-49-3 (Gastric Inhibitory Polypeptide)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
SB  - IM
MH  - Blood Glucose
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Gastric Inhibitory Polypeptide
MH  - Glucagon-Like Peptide 1
MH  - Humans
MH  - Incretins/therapeutic use
MH  - Insulin
MH  - Japan
OTO - NOTNLM
OT  - GIP/GLP-1 dual agonist
OT  - Non-communicable diseases (ncds)
OT  - Oral GLP-1R agonist
OT  - combination of long-acting basal insulin and GLP1R agonist
OT  - glimins
OT  - healthy life expectancy
OT  - once weekly basal insulin; imeglimin
OT  - type 2 diabetes mellitus
OT  - ultra-rapid acting insulin analogues
OT  - beta cell function
EDAT- 2021/09/01 06:00
MHDA- 2021/11/03 06:00
CRDT- 2021/08/31 05:33
PHST- 2021/09/01 06:00 [pubmed]
PHST- 2021/11/03 06:00 [medline]
PHST- 2021/08/31 05:33 [entrez]
AID - 10.1080/14656566.2021.1974401 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2021 Nov;22(16):2235-2249. doi: 
      10.1080/14656566.2021.1974401. Epub 2021 Oct 14.